BIOMAT Database Logo BIOMAT Database Logo

Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. 2003

Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Laboratory for Medicinal Chemistry (FFW), Ghent University, Harelbekestraat 72, B-9000 Gent, Belgium.

The affinity of a series of 2', 3'- and 5-modified thymidine analogues for Mycobacterium tuberculosis thymidine monophosphate kinase (TMPKmt) was evaluated. The affinities of several non-phosphorylated analogues are in the same order of magnitude as those of their phosphorylated congeners. In view of drug delivery problems associated with phosphorylated compounds, these 'free' nucleosides seem more promising leads in the search of TMPKmt inhibitors as novel anti-tuberculosis agents.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D009703 Nucleoside-Phosphate Kinase An enzyme that catalyzes reversible reactions of a nucleoside triphosphate, e.g., ATP, with a nucleoside monophosphate, e.g., UMP, to form ADP and UDP. Many nucleoside monophosphates can act as acceptor while many ribo- and deoxyribonucleoside triphosphates can act as donor. EC 2.7.4.4. Nucleoside Monophosphate Kinases,Kinase, Nucleoside-Phosphate,Kinases, Nucleoside Monophosphate,Monophosphate Kinases, Nucleoside,Nucleoside Phosphate Kinase
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013936 Thymidine A nucleoside in which THYMINE is linked to DEOXYRIBOSE. 2'-Deoxythymidine,Deoxythymidine,2' Deoxythymidine
D013942 Thymine Nucleotides Phosphate esters of THYMIDINE in N-glycosidic linkage with ribose or deoxyribose, as occurs in nucleic acids. (From Dorland, 28th ed, p1154) Thymidine Phosphates,Nucleotides, Thymine,Phosphates, Thymidine
D020128 Inhibitory Concentration 50 The concentration of a compound needed to reduce population growth of organisms, including eukaryotic cells, by 50% in vitro. Though often expressed to denote in vitro antibacterial activity, it is also used as a benchmark for cytotoxicity to eukaryotic cells in culture. IC50,Concentration 50, Inhibitory

Related Publications

Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Design of Mycobacterium tuberculosis thymidine monophosphate kinase inhibitors.
January 2003, Nucleosides, nucleotides & nucleic acids,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
July 2008, ChemMedChem,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium tuberculosis thymidine monophosphate kinase.
December 2011, Bioorganic & medicinal chemistry,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Thymidine 5' variants as inhibitors of thymidylate kinase.
July 1974, Journal of medicinal chemistry,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Dinucleotide analogues as inhibitors of thymidine kinase, thymidylate kinase, and ribonucleotide reductase.
July 1988, Journal of medicinal chemistry,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Synthesis and evaluation of 6-aza-2'-deoxyuridine monophosphate analogs as inhibitors of thymidylate synthases, and as substrates or inhibitors of thymidine monophosphate kinase in Mycobacterium tuberculosis.
March 2012, Chemistry & biodiversity,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Computer-assisted combinatorial design of bicyclic thymidine analogs as inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
January 2011, Journal of computer-aided molecular design,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Synthesis and evaluation of 5-substituted 2'-deoxyuridine monophosphate analogues as inhibitors of flavin-dependent thymidylate synthase in Mycobacterium tuberculosis.
July 2011, Journal of medicinal chemistry,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
A new family of inhibitors of Mycobacterium tuberculosis thymidine monophosphate kinase.
January 2007, Nucleosides, nucleotides & nucleic acids,
Veerle Vanheusden, and Philippe Van Rompaey, and Hélène Munier-Lehmann, and Sylvie Pochet, and Piet Herdewijn, and Serge Van Calenbergh
Rational design of 5'-thiourea-substituted alpha-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacterial growth.
November 2007, Journal of medicinal chemistry,
Copied contents to your clipboard!